New hope for prostate cancer: extended radioactive therapy shows promise

NCT ID NCT06531499

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a radioactive drug called Lutetium-177 vipivotide tetraxetan in men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The drug targets and delivers radiation directly to cancer cells. The study aims to see if giving up to 12 cycles of treatment is safe and how the radiation affects the body. About 106 men who have not had chemotherapy will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium-177 vipivotide tetraxetan (a radioactive drug that targets prostate cancer cells)
What this could lead to: If successful, this could lead to a longer treatment option for men with advanced prostate cancer who have not yet had chemotherapy, potentially controlling the disease for a longer period.
What could go wrong: This is an early Phase 1 trial with only 106 participants, so safety and effectiveness are not yet proven. The radioactive treatment may cause side effects like damage to healthy organs or bone marrow suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Mayo Clinic Rochester
RECRUITING

Rochester, Minnesota, 55905, United States
Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68130, United States
Novartis Investigative Site
RECRUITING

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site
RECRUITING

Wuppertal, North Rhine-Westphalia, 42283, Germany
Novartis Investigative Site
RECRUITING

Aachen, 52074, Germany
Novartis Investigative Site
RECRUITING

Berlin, 13353, Germany
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

München, 80377, Germany
Novartis Investigative Site
RECRUITING

Rostock, 18057, Germany
Novartis Investigative Site
RECRUITING

Nijmegen, Gelderland, 6500HB, Netherlands
Novartis Investigative Site
RECRUITING

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site
RECRUITING

Majadahonda, Madrid, 28222, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08041, Spain
Novartis Investigative Site
RECRUITING

Bellinzona, 6500, Switzerland
Novartis Investigative Site
RECRUITING

Bern, 3010, Switzerland
Novartis Investigative Site
RECRUITING

Sutton, Surrey, SM2 5PT, United Kingdom
Novartis Investigative Site
RECRUITING

Birmingham, West Midlands, B15 2TH, United Kingdom
Novartis Investigative Site
RECRUITING

Glasgow, G12 0YN, United Kingdom
Stanford University
RECRUITING

Palo Alto, California, 94304, United States
University of California LA
RECRUITING

Los Angeles, California, 90095, United States
Wash U School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.